Migraine Trial, Recruiting NCT07177885 Sponsor: University Hospital, Clermont-Ferrand Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT07177885
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who were born female and are not yet through menopause, between the ages of 18 and 50
  • Men who were born male, between the ages of 18 and 50
  • People who have been diagnosed with migraines (based on standard medical guidelines known as ICHD-3)
  • People who have been identified as either responding well or not responding well to a type of migraine medication called triptans (based on specific research criteria)
  • People who use triptans on their own or alongside other migraine treatments, such as anti-inflammatory painkillers, acetaminophen, ergotamine, opioids, or anti-nausea medications
  • Any dose or method of taking these medications is acceptable (for example, tablets, injections, or nasal sprays)
  • People who are part of a social security or public health insurance system

Who may not be able to join:

  • People who are under legal guardianship, court-appointed protection, or who have had their personal freedoms restricted in any legal way (confirm with trial site)
  • Women who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xavier Moisset, University Hospital, Clermont-Ferrand

Phone: 0033473754027

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 March 2026
Est. completion
1 March 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Plasma tryptophan levels

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov